Spotlight Series on Hepatitis C

U.S. News

FDA Fast Tracks AbbVie Hepatitis C Drug

May 8, 2013

According to AbbVie, the Food and Drug Administration (FDA) has given its new hepatitis C drug regimen a breakthrough therapy designation, which will speed up its potential approval in the United States. The FDA's designation stems from clinical trial results, which have shown a high response rate to the combination therapy in which patients receive 12–24 weeks of treatment with nearly one year of post-treatment follow-up.

Back to other news for May 2013

Adapted from:
Chicago Tribune
05.06.2013; Samantha Bomkamp

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.